NasdaqGS - Nasdaq Real Time Price USD

Vor Biopharma Inc. (VOR)

Compare

1.4200

+0.0300

+(2.16%)

At close: January 31 at 4:00:01 PM EST

1.4016

-0.02

(-1.30%)

After hours: January 31 at 6:45:15 PM EST

Vor Biopharma Inc. (VOR)'s Technical Outlook is Bright After Key Golden Cross

Is it a good or bad thing when a stock experiences a golden cross technical event?

Zacks 4 days ago

VOR
+2.16%
Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Mr. Erez Kalir to its Board of Directors. The appointment represents a new seat on Vor Bio’s Board of Directors, which has been created in connection with the recent private investment in public equity financing (PIPE) which was led by Reid Hoffman. Mr. Kalir will serve as the director designee of Reprogrammed Interchange, LLC, Mr. Ho

GlobeNewswire 23 days ago

VOR
+2.16%
Vor Biopharma Secures $55.6M for Cancer Therapy Trials

The latest announcement is out from Vor Biopharma ( (VOR) ). Vor Biopharma has entered into a Securities Purchase Agreement for a $55.6 million private placement to issue shares and warrants, with the proceeds intended to fund clinical and preclinical development and extend cash runway through 2025. The transaction involves significant stakeholders, including Reid Hoffman and RA Capital Management, and is expected to bolster Vor Bio’s efforts in advancing its clinical trials for cancer therapies

TipRanks last month

VOR
+2.16%
Vor Bio Secures $55.6 Million in PIPE Financing, Shares Surge Nearly 47%

The funds will support clinical trials for VCAR33ALLO and trem-cel therapies in 2025.

GuruFocus.com last month

VOR
+2.16%
Vor Bio Announces $55.6 Million Private Placement

Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the first half of 2025 and updated clinical data from Phase 1/2a VBP101 trial of trem-cel in combination with Mylotarg in the second half of 2025 Extends cash runway through release of updated data from VBP101 and VBP301 trials in 2025 CAMBRIDGE, Mass., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it has entered into a securi

GlobeNewswire last month

VOR
+2.16%
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplantTrem-cel + Mylotarg continue to demonstrate engraftment, shielding, and broadened therapeutic windowCompany has received supportive feedback from the FDA regarding a registrational clinical trial design CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, to

GlobeNewswire last month

VOR
+2.16%
Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update

Company to present trem-cel + Mylotarg clinical data update at American Society of Hematology (ASH) 2024 annual meetingHan Choi, M.D., LL.M, seasoned healthcare institutional investor, appointed as Chief Financial Officer CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended September 30, 2024, and provided a corporate update. “We are pleased with our opera

GlobeNewswire 2 months ago

VOR
+2.16%
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new Chief Financial Officer, effective immediately. Dr. Choi will join the Vor Bio leadership team and will report directly to the company’s President and Chief Executive Officer, Dr. Robert Ang. Dr. Choi brings to Vor Bio over twenty-five years of experience in public and private investment management,

GlobeNewswire 3 months ago

VOR
+2.16%
New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies

Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with significant potential opportunities across oncology, gene therapy, and autoimmune disorders CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced new clinical data from its ongoing Phase 1/2 VBP101 study of patient

GlobeNewswire 4 months ago

VOR
+2.16%
Here's Why Vor Biopharma (NASDAQ:VOR) Must Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 4 months ago

VOR
+2.16%
Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update

On-track for trem-cel + Mylotarg™ and VCAR33ALLO clinical updates in the second half of 2024 CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended June 30, 2024, and provided a corporate update. “We are pleased with the progress we have made with enrollment of both the trem-cel + Mylotarg and VCAR33ALLO clinical trials during the quarter,” said Dr. Robert A

GlobeNewswire 5 months ago

VOR
+2.16%
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of July 31, 2024, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 1,250 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 1,875 shares of Vor Bio’s common stock to one newly hired employee. The foregoing stock op

GlobeNewswire 5 months ago

VOR
+2.16%
Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

On-track for trem-cel and VCAR33ALLO clinical updates in the second half of 2024Trem-cel trial expanded to include patients with myelodysplastic syndromes (MDS); Mylotarg™ dosing has advanced to the third cohort CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended March 31, 2024, and provided a business update. “We are pleased with the strong enthusiasm fro

GlobeNewswire 8 months ago

VOR
+2.16%
Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences: The Citizens JMP Life Sciences Conference Fireside Chat: Tuesday, May 14, 2024 at 11:00 am ET Location: New York, NY A live webcast and archived replay of the fireside chat will be available on the investors section of www.vorbio.com. H.C. Wainwright 2nd Annual BioConnect Investor C

GlobeNewswire 8 months ago

VOR
+2.16%
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Research & Development at Blueprint Medicines, bringing a wealth of industry experience and expertise to Vor Bio's Board. In his role at Blueprint Medicines, Dr. Namouni has demonstrated exceptional leadership in building the company's fully in

GlobeNewswire 8 months ago

VOR
+2.16%
Why You Shouldn't Bet Against Vor Biopharma (VOR) Stock

Vor Biopharma (VOR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks 9 months ago

VOR
+2.16%
Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Simply Wall St. 9 months ago

VOR
+2.16%
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Trem-cel and VCAR33ALLO clinical trial data expected in the second half of 2024VCAR33ALLO granted Fast Track and Orphan Drug Designation by U.S. Food & Drug Administration Cash runway extends into second half of 2025 CAMBRIDGE, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2023, and provided a business update. “We are very pleased w

GlobeNewswire 10 months ago

VOR
+2.16%
Institutions own 36% of Vor Biopharma Inc. (NASDAQ:VOR) shares but private equity firms control 43% of the company

Key Insights Vor Biopharma's significant private equity firms ownership suggests that the key decisions are influenced...

Simply Wall St. 11 months ago

VOR
+2.16%
2 “Strong Buy” Penny Stocks That Could Rally All the Way to $10 (or More)

Are penny stocks a must-have or a must-avoid? Well, that depends on who you ask. There’s no middle ground when it comes to these tickers trading for less than $5 per share; those on the Street are either fans or harsh critics. Both sides make sense. The naysayers argue that the bargain price is just too good to be true, with it potentially indicating there are problems hiding beneath the surface like weak fundamentals or overwhelming headwinds. However, the investors that are pro-penny stocks ju

TipRanks 11 months ago

ATHA

VOR
+2.16%

Performance Overview

Return	VOR	S&P 500
YTD	+19.33%	+2.26%
1-Year	-41.56%	+22.65%
3-Year	-81.68%	+36.30%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Vor Biopharma Inc. (VOR)

Vor Biopharma Inc. (VOR)'s Technical Outlook is Bright After Key Golden Cross

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

Vor Biopharma Secures $55.6M for Cancer Therapy Trials

Vor Bio Secures $55.6 Million in PIPE Financing, Shares Surge Nearly 47%

Vor Bio Announces $55.6 Million Private Placement

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies

Here's Why Vor Biopharma (NASDAQ:VOR) Must Use Its Cash Wisely

Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

Vor Bio to Participate in Upcoming Investor Conferences

Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

Why You Shouldn't Bet Against Vor Biopharma (VOR) Stock

Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Institutions own 36% of Vor Biopharma Inc. (NASDAQ:VOR) shares but private equity firms control 43% of the company

2 “Strong Buy” Penny Stocks That Could Rally All the Way to $10 (or More)

Performance Overview